Innoviva Stock Crosses 200-Day Moving Average

Shares of the biotech company surge as analysts see upside potential.

Apr. 7, 2026 at 7:18am by Ben Kaplan

Got story updates? Submit your updates here. ›

An extreme close-up of complex, interlocking gears and levers in a muted industrial palette, conceptually representing the inner workings of a well-established financial institution.Innoviva's stock price surge reflects the stability and reliability of its royalty-based business model in the volatile biotech sector.San Francisco Today

Shares of Innoviva, Inc. (NASDAQ:INVA) crossed above their 200-day moving average on Monday, signaling a potential bullish trend for the biotech company's stock. The stock traded as high as $23.15 before closing at $23.02, up 0.1% on the day.

Why it matters

Crossing above the 200-day moving average is often seen as a bullish technical indicator, suggesting the stock may be poised for further gains. Innoviva's stock has been on an upward trajectory in recent months, buoyed by positive analyst sentiment and the company's royalty-focused business model.

The details

Innoviva, a San Francisco-based biotech firm, generates the majority of its revenue from royalties on respiratory therapies originally developed by its former affiliate and now marketed by GlaxoSmithKline. The company's stock has a consensus 'Moderate Buy' rating from analysts, who see further upside potential with a average price target of $34.80.

  • Innoviva's stock price crossed above its 200-day moving average of $20.50 on Monday, April 7, 2026.
  • The company reported strong Q4 2025 earnings on February 26, 2026, with revenue of $114.61 million and earnings per share of $1.94.

The players

Innoviva, Inc.

A San Francisco-based biotech company that generates revenue from royalties on respiratory therapies developed by its former affiliate and marketed by GlaxoSmithKline.

GlaxoSmithKline

A multinational pharmaceutical company that markets several long-acting inhaled products for COPD and asthma, for which Innoviva receives royalties.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, Grocery employee

What’s next

Analysts will be closely watching to see if Innoviva's stock can maintain its momentum and continue trading above the 200-day moving average, which could signal further upside potential.

The takeaway

Innoviva's royalty-focused business model and positive analyst sentiment have helped drive the stock's recent gains, underscoring the potential for biotech companies with established revenue streams to weather market volatility.